从粘膜感染到成功的癌症免疫治疗
Anne-Gaëlle Goubet1,2,3,4, Mathieu Rouanne1,2,5, Lisa Derosa1,2,6
1Gustave Roussy, Villejuif, France.
Nature reviews. Urology
|July 11, 2023
概括
免疫检查点阻断剂 (ICBs) 彻底改变了尿路癌症的治疗方法. 肠道和尿道细菌可能会提高ICB的有效性,提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 晚期泌尿道癌症越来越多地使用免疫检查点阻断剂 (ICB) 来治疗.
- 具有高突变负担和T细胞透的免疫性瘤对免疫疗法反应更好.
- 微生物群落在癌症治疗反应中的作用是一个新兴的研究领域.
研究的目的:
- 探索共生细菌对免疫检查点阻断剂在尿路癌症中的疗效的影响.
- 识别潜在的微生物目标,以增强抗癌免疫反应.
- 调查肠道和尿道微生物群与患者结局之间的联系.
主要方法:
- 对ICBs,瘤免疫学和尿路癌症中的微生物组的当前文献的综述.
- 对研究细菌感染和共生病对癌症免疫监测的影响的分析.
- 在微生物相互作用的背景下探索T细胞反应,B细胞活动和淋巴状结构.
主要成果:
- 尿路和肠道共生物,包括BCG和尿病原性大肠杆菌,似乎影响了对ICBs的长期反应.
- 在健康和受瘤影响的尿道之间存在着开始性菌群的差异.
- 抗生素可以影响尿路恶性瘤的预后,突出显示细菌的作用.
结论:
- 交叉体细菌在癌症免疫监测和对免疫治疗的反应中发挥着重要作用.
- 对泌尿病原体初生的免疫反应可以被利用来开发新的免疫辅助剂.
- 将针对微生物组的策略与ICB结合起来,可能为尿路癌症提供更好的治疗结果.
更多相关视频
相关概念视频
Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Cancer Vaccines
419
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
419
Cell-mediated Immune Responses
69.0K
Overview
69.0K


